

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b> <b>Starpharma Holdings Ltd</b>
<b>ABN</b> <b>20 078 532 180</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Dr Jacinth K Fairley
<b>Date of last notice</b>	29 February 2012

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	
<b>Date of change</b>	5 October 2012
<b>No. of securities held prior to change</b>	1. 1,619,197 Ordinary Shares (direct) 2. 30,000 Ordinary Shares (indirect) Dr Ian Fraser 3. 375,000 Performance Rights (SPLAK)
<b>Class</b>	Ordinary Shares
<b>Number acquired</b>	125,000 Ordinary fully paid shares (direct)
<b>Number disposed</b>	375,000 Performance Rights (SPLAK) (125,000 vested; 250,000 lapsed)
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil

---

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

No. of securities held after change	1. 1,744,197 Ordinary Shares (direct) 2. 30,000 Ordinary Shares (indirect) Dr. Ian Fraser 3. Nil Performance Rights (SPLAK)
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	(i) Allotment of 125,000 ordinary fully paid shares following vesting of Performance Rights on 30 September 2012.  (These shares will be subject to a holding lock until 30 Sep 2013 provided that the shares may be released early if certain events occur, in accordance with the Rules of the Starpharma Employee Performance Rights Plan.)  (ii) Lapse of 250,000 Performance Rights due to the applicable vesting conditions not being satisfied.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

**Part 3 – +Closed period**

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.